长效卡博特韦和rilpivirine治疗的药物水平及非持续病毒抑制情况的见解 - Suppr

Insights on Drug Levels and Non-Sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy.

作者信息

Gutiérrez Félix, Fernández-González Marta, Ledesma Christian, Losada-Echeberría María, Barrajón-Catalán Enrique, Masiá Mar

机构信息

Infectious Diseases Unit, Hospital General Universitario de Elche, Elche, Spain.

Department of Clinical Medicine, Universidad Miguel Hernández, Alicante, Spain.

出版信息

Clin Infect Dis. 2025 Aug 1;81(1):e5-e6. doi: 10.1093/cid/ciae617.

DOI:10.1093/cid/ciae617

PMID:39673180

Abstract

摘要

相似文献

Insights on Drug Levels and Non-Sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy.长效卡博特韦和rilpivirine治疗的药物水平及非持续病毒抑制情况的见解

Clin Infect Dis. 2025 Aug 1;81(1):e5-e6. doi: 10.1093/cid/ciae617.

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.长效肌内注射卡替拉韦和利匹韦林治疗成人 HIV-1 感染（LATTE-2）：一项随机、开放标签、2b 期、非劣效性试验的 96 周结果。

Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24.

Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir/Rilpivirine With Initial Viremia.初始病毒血症的HIV感染者开始使用长效卡博特韦/利匹韦林治疗48周时的病毒抑制率

Clin Infect Dis. 2025 Apr 30;80(4):864-870. doi: 10.1093/cid/ciae500.

Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort.长效卡博特韦/利匹韦林在病毒学抑制的HIV感染者中治疗中断的有效性及预测因素：来自伊科纳队列的真实数据

J Antimicrob Chemother. 2025 Aug 1;80(8):2169-2178. doi: 10.1093/jac/dkaf184.

Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the Potency of Cabotegravir or Rilpivirine.HIV-1 亚型 A6/A1 整合酶序列对卡替拉韦或利匹韦林效力的影响。

Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0170221. doi: 10.1128/AAC.01702-21. Epub 2022 Jan 3.

Long-acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re-suppression outcomes in virally suppressed individuals living with HIV.观察性队列研究中长效注射用卡博特韦和利匹韦林：对病毒学抑制的HIV感染者病毒学失败、耐药性和重新抑制结果的系统评价

HIV Med. 2025 Aug;26(8):1267-1288. doi: 10.1111/hiv.70057. Epub 2025 Jun 13.

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.长效卡博替拉韦加利匹韦林用于治疗成人 HIV-1 感染：随机、开放标签、3 期 FLAIR 研究的 96 周结果。

Lancet HIV. 2021 Apr;8(4):e185-e196. doi: 10.1016/S2352-3018(20)30340-4.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.长效卡替拉韦和利匹韦林每 2 个月给药 1 次用于治疗成人 HIV-1 感染（ATLAS-2M）：96 周结果：一项随机、多中心、开放性标签、3b 期、非劣效性研究。

Lancet HIV. 2021 Nov;8(11):e679-e689. doi: 10.1016/S2352-3018(21)00185-5. Epub 2021 Oct 11.

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.在感染 HIV-1 的成人中直接注射或口服先导药物启动长效卡替拉韦/利匹韦林：FLAIR 研究开放标签 3 期第 124 周结果。

Lancet HIV. 2021 Nov;8(11):e668-e678. doi: 10.1016/S2352-3018(21)00184-3. Epub 2021 Oct 14.

Virological History Predicts Non-sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy, Independent of Pharmacokinetic Parameters.病毒学病史可预测长效卡博特韦和利匹韦林治疗的病毒抑制未持续，且独立于药代动力学参数。

Clin Infect Dis. 2025 Apr 30;80(4):842-853. doi: 10.1093/cid/ciae475.

引用本文的文献

Influence of patient characteristics and oral lead-in on long-acting cabotegravir and rilpivirine pharmacokinetics and outcomes in people with HIV: a real-world study.患者特征和口服导入期对长效卡博特韦和利匹韦林在HIV感染者中的药代动力学及治疗结果的影响：一项真实世界研究

Antimicrob Agents Chemother. 2025 Jul 2;69(7):e0014525. doi: 10.1128/aac.00145-25. Epub 2025 Jun 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Insights on Drug Levels and Non-Sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献